Preclinical studies suggest that exogenous surfactant may be of value in the treatment of the acute respiratory distress syndrome (ARDS), and two phase 2 clinical trials have shown a trend toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results